Reduction of interleukin-17-induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin-4

Arthritis and Rheumatism

Volumn 43, Issue 6, 2000, Pages 1300-1306

  Lubberts, Erik ^a   Joosten, Leo A B ^a   Van De Loo, Fons A J ^a   Van Den Bersselaar, Liduine A M ^a   Van Den Berg, Wim B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; N5 (1 IMINOETHYL)ORNITHINE; NITRIC OXIDE; PROTEOGLYCAN; RECOMBINANT INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; PATELLA; PRIORITY JOURNAL; PROTEOGLYCAN SYNTHESIS;

ANIMALS; CARTILAGE, ARTICULAR; CHONDROCYTES; CULTURE TECHNIQUES; FEMALE; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKIN-4; MICE; MICE, INBRED C57BL; NITRIC OXIDE; PATELLA; PROTEOGLYCANS;

EID: 0034044183     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200006)43:6<1300::AID-ANR12>3.0.CO;2-D     Document Type: Article

References (43)

1. Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
2. Feldmann M, Elliot MJ, Woody JN, Maini RN. Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol 1997;64:283-350.
3. Elliot MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen J, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
4. Rankin ECC, Choy EHS, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor α antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334-42.
5. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombhinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
6. Van de Loo AAJ, van den Berg WB. Effects of murine recombinant interleukin-1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis 1990;49:238-45.
7. Van de Loo FAJ, Joosten LAB, van Lent PLEM, Arntz OJ, van den Berg WB. Role of interleukin-1. tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen-and zymosan-induced arthritis. Arthritis Rheum 1995;38:164-72.
8. Van de Loo FAJ, Arntz OJ, van Enckevort FHJ, van Lent PLEM. van den Berg WB. Reduced cartilage proteoglycan loss during zymosan-induced gonarthritis in NOS2-deficient mice and in anti-interleukin-1-treated wild-type mice with unabated joint inflammation. Arthritis Rheum 1998;41:634-46.
9. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 1996;39:797-809.
10. Van Lent PLEM, van den Bersselaar LAM, van de Hoek AEM, van de Loo AAJ, van den Berg WB. Cationic immune complex arthritis in mice - a new model. Synergistic effect of complement and interleukin-1. Am J Pathol 1992;140:1451-61.
11. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996;183:2593-603.
12. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Springs MK, et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995;155:5483-506.
13. Chahaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999;42:963-70.
14. Attur MG, Patel RN, Abramson SB, Amin AR. Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage. Arthritis Rheum 1997;40:1050-3.
15. Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998;161:409-14.
16. Katsikis PD, Chu C-Q, Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of interleukin-10 (IL-10) in rheumatoid arthritis. J Exp Med 1994;179:1517-27.
17. Llorente L, Richaud-Patin Y, Fior R, Alcocer-Varela J, Wijdenes J, Fourrier BM, et al. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus: a potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 1994; 37:1647-55.
18. Cush JJ, Splawski JB, Thomas R, McFarlin JE, Schulze-Koops H, Davies LS, et al. Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum 1995;38:96-104.
19. Cohen SBA, Katsikis PD, Chu C-Q, Thomassen H, Webb LMC, Maini RN, et al. High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane. Arthritis Rheum 1995;38:946-52.
20. Chomarat P, Vannier E, Dechanet J, Rissoan MC, Banchereau J, Dinarello CA, et al. Balance of IL-1 receptor antagonist/IL-1β in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 1995;154:1432-9.
21. Isomäki P, Luukkainen R, Saario R, Toivanen P, Punnonen J. Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Arthritis Rheum 1996;39:386-95.
22. Kasama T, Strieter RM, Lukacs NW, Lincoln PM, Burdick MD, Kunkel SL. Interleukin-10 expression and chemokinc regulation during the evolution of murine type II collagen-induced arthritis. J Clin Invest 1995;95:2868-76.
23. Iannone F, Lapadula G, De Bari C, Acquista CA, Covelli M, Patella V, et al. Increased intracellular levels of interleukin-10 in osteoarthritic human articular chondrocytes [abstract]. Arthritis Rheum 1996;39 Suppl 9:S269.
24. Yeh L, Augustine AJ, Lee P, Riviere LR, Sheldon A. Interleukin-4, an inhibitor of cartilage breakdown in bovine articular cartilage explants. J Rheumatol 1995;22:1740-6.
25. Shingu M, Miyauchi S, Nagai Y, Yasutake C, Horie K. The role of IL-4 and IL-6 in IL-1-dependent cartilage matrix degradation. Br J Rheumatol 1995;34:101-6.
26. Cawston TE, Ellis AJ, Bigg H, Curry V, Lean E, Ward D. Interleukin-4 blocks the release of collagen fragments from bovine nasal cartilage treated with cytokines. Biochim Biophys Acta 1996;1314:226-32.
27. Lubberts E, Joosten LAB, van den Bersselaar L, Helsen MMA, Bakker AC, van Meurs JBJ, et al. Adenoviral vector-mediated overexpression of interleukin-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction. J Immunol 1999;163:4546-56.
28. Salter DM, Nuki G, Wright MO. IL-4 inhibition of cartilage breakdown in bovine articular explants [letter]. J Rheumatol 1996;23:1314-5.
29. Lubberts E, Joosten LAB, Helsen MMA, van den Berg WB. Regulatory role of interleukin-10 in joint inflammation and cartilage destruction in murine streptococcal cell wall (SCW) arthritis: more therapeutic benefit with IL-4/IL-10 combination therapy than with IL-10 treatment alone. Cytokine 1998;10:361-9.
30. Van Roon JAG, van Roy JLAM, Gmelig-Meyling FHJ, Lafeber FPJG, Bijlsma JWJ. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum 1996;39:829-35.
31. Van Beuningen HM, Arntz OJ, van den Berg WB. Insulin-like growth factor stimulation of articular chondrocyte proteoglycan synthesis: availability and response at different ages. Br J Rheumatol 1993;32:606-15.
32. Perreti M, Szabo C, Thiemermann C. Effect of interleukin-4 and interleukin-10 on leucocyte migration and nitric oxide production in the mouse. Br J Pharmacol 1995;116:2251-7.
33. Weiss G, Bogdan C, Hentze MW. Pathways for the regulation of macrophage iron metabolism by the anti-inflammatory cytokines IL-4 and IL-13. J Immunol 1997;158:420-5.
34. Van den Berg WB, van de Loo FAJ, Zwarts WA, Otterness IG. Effects of murine recombinant interleukin-1 on intact homologous articular cartilage: a quantitative and autoradiographic study. Ann Rheum Dis 1988;47:855-63.
35. Jovanovic DV, DiBattista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1β and TNF-α, by human macrophages. J Immunol 1998;160:3513-21.
36. Hauselmann HJ, Stefanovic-Racie M, Michel BA, Evans CH. Differences in nitric oxide production by superficial and deep human articular chondrocytes: implications for proteoglycan turnover in inflammatory joint diseases. J Immunol 1998;160:1444-8.
37. Lotz M. The role of nitric oxide in articular cartilage damage. Rheum Dis Clin North Am 1999;25:269-82.
38. Amin AR, Attur M, Abramson SB. Nitric oxide synthase and cyclooxygenases: distribution, regulation, and intervention in arthritis. Curr Opin Rheumatol 1999;11:202-9.
39. Miossec P, van den Berg W. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 1997;40:2105-15.
40. Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999;162:1246-51.
41. Shalom-Barak T, Quach J, Lotz M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-κB. J Biol Chem 1998; 273:27467-73.
42. Lotz M, Bober L, Narula S, Dadler J. IL-17 promotes cartilage degradation [abstract]. Arthritis Rheum 1996;39 Suppl 9:S120.
43. Dudler J, Busso N, Péclat V, Lotz M, So A. In vivo effects of murine recombinant interleukin-17 on synovial joint in mice [abstract]. Arthritis Rheum 1997;40 Suppl 9:S273.